首页> 外文期刊>Contraception >Suppression of ovarian activity with a low-dose 21/7-day regimen oral contraceptive containing ethinylestradiol 20 mcg/drospirenone 3 mg in Japanese and Caucasian women
【24h】

Suppression of ovarian activity with a low-dose 21/7-day regimen oral contraceptive containing ethinylestradiol 20 mcg/drospirenone 3 mg in Japanese and Caucasian women

机译:抑制含有低剂量21/7天方案口服含有乙尼雌二醇20 mcg / droposphirenone 3mg的日本和白种人女性的卵巢运动

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Two studies assessed the effect of a low-estrogen-dose 21/7-day oral contraceptive containing ethinylestradiol and drospirenone (EE 20 mcg/drsp 3 mg) on ovarian activity in Japanese and Caucasian women. Study Design: Study 1 was conducted in Japanese women (20-35 years), and Study 2 was conducted in Caucasian women (18-35 years). All women received EE 20 mcg/drsp 3 mg in a 21-day active pill regimen. The primary endpoint was the proportion of women with ovulation inhibition (Hoogland score <6; as assessed by transvaginal ultrasonography) during treatment cycle 2. Results: Japanese (n=23) and Caucasian (n=30) women received two cycles of study treatment. During treatment cycle 2, ovulation was inhibited in 100% and 92.9% of Japanese and Caucasian women, respectively. Conclusions: EE 20 mcg/drsp 3 mg in a 21/7-day regimen provides comparable ovarian suppression in Japanese and Caucasian women, with normal ovarian function resuming shortly after treatment end in both populations.
机译:背景:两项研究评估了含有乙尼雌二醇和Droprosphirenone(EE 20 MCG / DRSP 3 Mg)的低雌激素剂量21/7天口服避孕药(EE 20 mcg / DRSP 3 mg)的效果。研究设计:研究1是在日本女性(20-35岁)中进行的,研究2在高加索妇女(18-35岁)中进行。所有女性在21天的活性药丸方案中收到EE 20 MCG / DRSP 3毫克。主要终点是患有排卵抑制的妇女的比例(Hoogland评分<6;如治疗循环期间评估)。结果:日本(n = 23)和白种人(n = 30)妇女接受了两个研究治疗循环。在治疗周期2期间,分别在100%和92.9%的日本和高加索妇女中抑制排卵。结论:EE 20 McG / DRSP 3毫克在21/7天的方案中提供日本和白人女性的相当卵巢抑制,在治疗结束后不久恢复正常的卵巢功能。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号